CHUNGBUK NATIONAL UNIVERSITY HOSPITAL

Korean Hospitals Secure Approval for SK Biopharmaceuticals' Cenobamate for Epilepsy Treatment

3 months ago

• Two major Korean university hospitals have received therapeutic use approval for cenobamate in epilepsy treatment, marking the first medical team applications for this indication since SK Biopharmaceuticals' 2022 approval. • Dong-A ST has submitted a domestic product license application for cenobamate, aiming for market launch and reimbursement in 2026 across 30 countries including Korea and various Asian markets. • Cenobamate, marketed as XCOPRI in the US, has demonstrated superior efficacy compared to existing treatments and has been prescribed to over 140,000 patients, offering hope for drug-resistant epilepsy cases.

South Korea Launches First Decentralized Clinical Trial Program with $3.3M Investment

4 months ago

Korea National Enterprise for Clinical Trials (KoNECT) has initiated the country's first decentralized clinical trial (DCT) pilot project, backed by a 4.5 billion won ($3.3 million) government investment over five years. The program, involving seven major medical institutions, will initially focus on approved drugs for mild conditions, allowing patients to participate in trials from home while maintaining regulatory compliance.

Study Highlights Efficacy and Safety of SGLT2 Inhibitors in Type 2 Diabetes Management

a year ago

A recent study evaluates the long-term efficacy and safety of Sodium-glucose co-transporter 2 (SGLT2) inhibitors in managing type 2 diabetes (T2D), revealing significant improvements in glycemic control and body weight reduction. However, it also notes an increased prevalence of adverse events and drug discontinuation, especially among elderly patients.